Cargando…
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
Recent phase II trials have shown that BRAF/MEK inhibitors and immune checkpoint inhibitors are active in patients with melanoma brain metastases (MBM), reporting intracranial disease control rates of 50–75%. Furthermore, retrospective analyses suggest that combining stereotactic radiosurgery with i...
Autores principales: | Kuske, Marvin, Rauschenberg, Ricarda, Garzarolli, Marlene, Meredyth-Stewart, Michelle, Beissert, Stefan, Troost, Esther G. C., Glitza, Oliva Isabella Claudia, Meier, Friedegund |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061393/ https://www.ncbi.nlm.nih.gov/pubmed/29417399 http://dx.doi.org/10.1007/s40257-018-0346-9 |
Ejemplares similares
-
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020) -
Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment
por: Steininger, Julian, et al.
Publicado: (2023) -
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
por: Steininger, Julian, et al.
Publicado: (2021) -
Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma
por: Linge, Annett, et al.
Publicado: (2018) -
Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
por: Hellmund, Peter, et al.
Publicado: (2020)